IP Library › Granted Patent US 12,643,924
Granted Patent B2
US 12,643,924 · App. 18/303,093 · Granted Jun 2, 2026

Cardiac-specific targeting-peptide (CTP), compositions, and uses thereof

Inventor: Maliha Zahid (Gibsonia, PA)
Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
C07K7/08A61K38/00C07K2319/10C07K2319/60C12Y114/99003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,643,924
App. No.
18/303,093
Granted
Jun 2, 2026
Kind
B2
Abstract

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Cardiac Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the heart. Also disclosed are subsequent generations of this Cardiac Targeting Peptide with improved, higher efficiency of cardiac uptake for CTP-mediated delivery of antiarrhythmics subjects for treating Atrial fibrillation or Ventricular fibrillation, CTP-mediated delivery of neuregulin-1β for treating systolic heart failure (SHF), and Szeto-Schiller peptides for treatment of diastolic congestive heart failure, among other applications.

Claims (8)

1 . A compound consisting of a peptide covalently linked, via an ester linkage, a disulfide linker, a peptide bond, a thioester bond, or a carbamate bond, to a cargo selected from the group consisting of: a nucleic acid, a carbohydrate, a lipid, a small molecule, or a combination thereof, wherein the peptide consists of the amino acid sequence of SQYSRT (SEQ ID NO: 5).

2 . The compound of claim 1 , wherein the cargo is a small molecule.

3 . The compound of claim 2 , wherein the small molecule is linked upstream of the N-terminus of the peptide.

4 . The compound of claim 1 , wherein the cargo is amiodarone.

5 . The compound of claim 1 , wherein the peptide is cyclized.

6 . A method of selectively delivering a cargo into a cardiac tissue of a subject, the method comprising administering the compound of claim 1 to the subject.

7 . A method of treating a human subject suffering from a cardiac condition selected from the group consisting of atrial arrhythmia and ventricular arrhythmia, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a compound consisting of a peptide covalently linked via an ester linkage, a disulfide linker, a peptide bond, a thioester bond, or a carbamate bond to an anti-arrhythmic compound, wherein the peptide consists of the amino acid sequence of SQYSRT (SEQ ID NO: 5).

8 . The method of claim 7 , wherein the atrial arrhythmia or ventricular arrhythmia is selected from the group consisting of atrial fibrillation, premature ventricular contractions, ventricular tachycardia, and ventricular fibrillation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2026
From: ZAHID, MALIHA
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 074347/0542 →
Continuity (5)
Continuation 17056193
Provisional Application 62811077 · Feb 27, 2019
Provisional Application 62778033 · Dec 11, 2018
Provisional Application 62675307 · May 23, 2018
Related Publication 20230406882A1 · Dec 21, 2023
References Cited (68)
US 5911983A · Barranger et al. · 1999 [cited by applicant]
US 6063576A · Keating · 2000 [cited by examiner]
US 8618061B2 · Szeto · 2013 [cited by applicant]
US 9249184B2 · Robbins · 2016 [cited by examiner]
US 9550981B2 · Chin · 2017 [cited by examiner]
US 20020061299A1 · French · 2002 [cited by applicant]
US 20030219497A1 · Otterbein et al. · 2003 [cited by applicant]
US 20050112128A1 · McKinsey et al. · 2005 [cited by applicant]
US 20060084606A1 · Szeto · 2006 [cited by applicant]
US 20100221235A1 · Arranz · 2010 [cited by applicant]
US 20100310495A1 · Schneider et al. · 2010 [cited by applicant]
US 20120009193A1 · Brown · 2012 [cited by examiner]
US 20120244136A1 · Robbins et al. · 2012 [cited by applicant]
US 20120277158A1 · Castaigne et al. · 2012 [cited by applicant]
US 20150297742A1 · Strieker et al. · 2015 [cited by applicant]
US 20150307582A1 · Xu et al. · 2015 [cited by applicant]
US 20150328315A1 · Kalifa · 2015 [cited by examiner]
US 20160106800A1 · Szeto et al. · 2016 [cited by applicant]
CN 102766258A · 2012 [cited by applicant]
WO WO2003079972A2 · 2003 [cited by applicant]
WO WO2008045976A2 · 2008 [cited by applicant]
WO WO2010033868A2 · 2010 [cited by examiner]
WO WO2018090042A1 · 2018 [cited by applicant]
Zimetbaum, Amiodarone for Atrial Fibrillation, n engl j med 356;9:935-941. (Year: 2007). [cited by examiner]
Claro, JC, Candia, R, Rada, G, Baraona, F, Larrondo, F, Letelier, LM., Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database of Systematic Reviews 2015, Issue 12… [cited by examiner]
Bhat et al., Lead discovery and optimization strategies for peptide macrocycles, European Journal of Medicinal Chemistry 94 (2015) 471e479. http://dx.doi.org/10.1016/j.ejmech.2014.07.083 (Year: 2015). [cited by examiner]
NlpCP60 family protein [ [cited by examiner]
Montigiani et al., J. Mol. Biol. (1996) 258, 6-13 (Year: 1996). [cited by examiner]
Morrison and Weiss, Current Opinion in Chemical Biology 2001, 5:302-307 (Year: 2001). [cited by examiner]
Ngambenjawong et al., Bioconjugate Chem. 2016, 27, 2854-2862 (Year: 2016). [cited by examiner]
Gunasekera et al., ChemBioChem 2018, 19, 931-939 (Year: 2018). [cited by examiner]
Alanine Scan—Mimotopes—archive image, Published 2012, Examiner generated PDF; https://web.archive.org/web/ 20161106145413/http://www. mimotopes .com/peptideLibraryScreening .asp?id =94 (Year: 2012). [cited by applicant]
Arap et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model”, [cited by applicant]
Castel et al. (2011) “Phage Display of Combinatorial Peptide Libraries: Application to Antiviral Research,” Molecules 16:3499-3518. [cited by applicant]
Frantz et al., “Absence of NF-κb Subunit p50 Improves Heart Failure after Myocardial Infarction”, [cited by applicant]
Jiang et al., “Acute Protection of Ischemic Heart by FGF-2: Involvement of FGF-2 Receptors and Protein Kinase C”, [cited by applicant]
Kamide et al. (2010) “Isolation of novel cell-penetrating peptides from a random peptide library using in vitro virus and their modifications,” International Journal of Molecular Medicine 25:41-51. [cited by applicant]
Kawano et al., “Blockade of NF-κb Improves Cardiac Function and Survival after Myocardial Infarction”, [cited by applicant]
Kelly et al., “In Vivo Phage Display Selection Yields Atherosclerotic Plaque Targeted Peptides for Imaging”, Molecular Imaging and Biology, 8(4):201-207, 2006. [cited by applicant]
Li et al., “Gene Therapy with Extracellular Superoxide Dismutase Protects Conscious Rabbits Against Myocardial Infarction”, [cited by applicant]
Li et al., “Gene Therapy with iNOS Provides Long-Term Protection Against Myocardial Infarction Without Adverse Functional Consequences”, [cited by applicant]
Lu et al., “Targeting of Embryonic Stem Cells by Peptide-Conjugated Quantum Dots”, [cited by applicant]
McGuire et al., “In vitro Selection of a Peptide with High Selectivity for Cardiomyocytes In vivo”, [cited by applicant]
Melo et al., “Gene Therapy Strategy for Long-Term Myocardial Protection Using Adena-Associated Virus-Mediated Delivery of Heme Oxygenase Gene”, [cited by applicant]
Mi et al., “Identification of a Synovial Fibroblast-Specific Protein Transduction Domain for Delivery of Apoptotic Agents to Hyperplastic Synovium”, [cited by applicant]
Molenaar et al., “Uptake and Processing of Modified Bacteriophage M13 in Mice: Implications for Phage Display”, [cited by applicant]
Okada et al., “Postinfarction Gene Therapy Against Transforming Growth Factor-β signal Modulates Infarct Tissue Dynamics and Attenuates Left Ventricular Remodeling and Heart Failure”, [cited by applicant]
Pachori et al. (2004) “Hypoxia-regulated Therapeutic Gene as a Preemptive Treatment Strategy Against Ischemia/Reperfustion Injury,” PNAS 101(33):12282-12287. [cited by applicant]
Pasqualini et al., “Organ Targeting In Vivo Using Phage Display Peptide Libraries”, [cited by applicant]
Pleger et al., “S100Al Gene Therapy Preserves in Vivo Cardiac Function after Myocardial Infarction”, [cited by applicant]
Positional Scan—Mimotopes—Archive image, Published 2016, Examiner generated PDF; https://web.archive.org/web/ 20160412054617 /http://www. mimotopes .com/peptideLibraryScreening .asp?id =92 (Year: 2016). [cited by applicant]
Rogers et al., “Temporal Trends in the Treatment of Over 1.5 Million Patients With Myocardial Infarction in the U.S. from 19990 Through 1999: The National Registry of Myocardial Infarction 1, 2 and 3”, [cited by applicant]
Roncalli et al., “Sonic Hedgehog-Induced Functional Recovery After Myocardial Infarction Is Enhanced by AMD3100-Mediated Progenitor-Cell Mobilization”, [cited by applicant]
Rákos et al., “Evans Blue Fluorescence Permits the Rapid Visualization of Non-Intact Cells in the Perilesional Rim of Cold-Injured Rat Brain”, [cited by applicant]
Segvich et al., “Identification of Peptides with Targeted Adhesion to Bone-Like Mineral via Phage Display and Computational Modeling”, [cited by applicant]
Segvich et al., “The Absorption of Preferential Binding Peptides to Apatite-Based Materials”, [cited by applicant]
Szeto HH, (2006) “Cell-permeable, Mitochondrial-targeted, Peptide Antioxidants,” The AAPS Journal 8(2):E277-E283. [cited by applicant]
Traboulsi et al. (2015) “Macrocyclic Cell Penetrating Peptides: A Study of Structure-Penetration Properties,” Bioconjugate Chemistry 26(3):405-411. [cited by applicant]
Truncation—Mimotopes—archive image, Published 2012, Examiner generated PDF; https://web.archive.org/web/ 20161106145333/http://www. mimotopes .com/peptideLibraryScreening .asp?id =91 (Year: 2012). [cited by applicant]
Wiviott et al., “Performance of the Thrombolysis In Myocardial Infarction Risk Index in the National Registry of Myocardial Infarction-3 and -4: A Simple Index That Predicts Mortality in ST-Segment Elevation Myocardial … [cited by applicant]
Written Opinion for International Application No. PCT/US2019/033551 dated Oct. 24, 2019. [cited by applicant]
Yao et al., “Targeting Pancreatic Islets with Phage Display Assisted by Laser Pressure Catapult Microdissection”, [cited by applicant]
Zahid et al., Aug. 17, 2010, Identification of a Cardiac Specific Protein Transduction Domain by In Vivo Biopanning using a M 13 Phage peptide Display Library in Mice, PLoS One, 5(8): 11 pages. [cited by applicant]
Zahid, 2009, Targeting the Heart Using In Vivo Phage Display, University of Pittsburgh, Doctoral thesis, 132 pages. [cited by applicant]
Zahid, et al. (2016) “Targeting the Heart Utilizing a Novel Cell Penetrating Peptide,” International Academy of Cardiology, Annual Scientific Sessions 2016 21st World Congress on Heart Disease. Conference Abstract (Onli… [cited by applicant]
Zahid, et al. (2017) “A Novel Cell Penetrating Peptide, Cardiac Targeting Peptide Appears to Utilize Cardiac Channels for Transduction.” International Academy of Cardiology, Annual Scientific Sessions 2017 22nd World Co… [cited by applicant]
Zhang et al., “Molecular Profiling of Heart Endothelial Cells”, [cited by applicant]
Lu, M. et al. “Reversing cardiac hypertrophy and heart failure using a cardiac targeting peptide linked to miRNA106a,” Clin. Transl. Med., 15:e70432, 22 pages (2025). [cited by applicant]